Viking Therapeutics Statistics
Share Statistics
Viking Therapeutics has 111.44M shares outstanding. The number of shares has increased by 1.9% in one year.
| Shares Outstanding | 111.44M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.58% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 107.97M |
| Failed to Deliver (FTD) Shares | 24.75K |
| FTD / Avg. Volume | 0.56% |
Short Selling Information
The latest short interest is 18.30M, so 16.42% of the outstanding shares have been sold short.
| Short Interest | 18.30M |
| Short % of Shares Out | 16.42% |
| Short % of Float | 16.93% |
| Short Ratio (days to cover) | 5.09 |
Valuation Ratios
The PE ratio is -20.44 and the forward PE ratio is -39.69.
| PE Ratio | -20.44 |
| Forward PE | -39.69 |
| PS Ratio | 0 |
| Forward PS | 106.5 |
| PB Ratio | 5.04 |
| P/FCF Ratio | -23.93 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Viking Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.19, with a Debt / Equity ratio of 0.
| Current Ratio | 19.19 |
| Quick Ratio | 19.19 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.36 |
| Cash Flow / Debt | -58.23 |
| Interest Coverage | -1145.76 |
Financial Efficiency
Return on equity (ROE) is -0.25% and return on capital (ROIC) is -28.83%.
| Return on Equity (ROE) | -0.25% |
| Return on Assets (ROA) | -0.23% |
| Return on Capital (ROIC) | -28.83% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -2.86M |
| Employee Count | 30 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 59.74% in the last 52 weeks. The beta is 0.99, so Viking Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.99 |
| 52-Week Price Change | 59.74% |
| 50-Day Moving Average | 50.18 |
| 200-Day Moving Average | 59.68 |
| Relative Strength Index (RSI) | 25.08 |
| Average Volume (20 Days) | 4.39M |
Income Statement
| Revenue | n/a |
| Gross Profit | -292.00K |
| Operating Income | -100.83M |
| Net Income | -85.89M |
| EBITDA | -100.83M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.91 |
Balance Sheet
The company has 55.52M in cash and 1.26M in debt, giving a net cash position of 54.26M.
| Cash & Cash Equivalents | 55.52M |
| Total Debt | 1.26M |
| Net Cash | 54.26M |
| Retained Earnings | -377.94M |
| Total Assets | 937.89M |
| Working Capital | 910.96M |
Cash Flow
In the last 12 months, operating cash flow was -73.38M and capital expenditures 0, giving a free cash flow of -73.38M.
| Operating Cash Flow | -73.38M |
| Capital Expenditures | 0 |
| Free Cash Flow | -73.38M |
| FCF Per Share | -0.78 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
VKTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -2.68% |
| FCF Yield | -1.94% |
Analyst Forecast
The average price target for VKTX is $109.5, which is 222.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $109.5 |
| Price Target Difference | 222.4% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
Scores
| Altman Z-Score | 107.57 |
| Piotroski F-Score | 3 |